Umbralisib is an orally active morpholino-pyrimidine that selectively inhibits phosphoinositide 3-kinase delta and casein kinase-1 epsilon, reshaping chronic lymphocytic leukemia T-cell function and enabling targeted therapy for B-cell malignancies.
Usually ships within 24 hours.